Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CRDF

Cardiff Oncology, Inc.

Healthcare | Biotechnology

Market prices for CRDF are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.60

Cardiff Oncology, Inc. (NASDAQ: CRDF) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:13 UTC.

What Cardiff Oncology, Inc. does

Oncolytics is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor, to treat various cancers by combining it with standard-of-care therapies. The company's lead drug candidate is designed to be highly selective for PLK1 and has demonstrated synergistic effects in laboratory and animal studies when combined with multiple classes of cancer drugs.

Summarized from Cardiff Oncology, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.60

Revenue, margins & earnings

FY2021: net loss $28M on revenue $359,000$359,000FY2021FY2022: net loss $39M on revenue $386,000$386,000FY2022FY2023: net loss $41M on revenue $488,000$488,000FY2023FY2024: net loss $45M on revenue $683,000$683,000FY2024FY2025: net loss $46M on revenue $593,000$593,000FY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-07-16
Most recent filed transactions — July 2026:
  • 2026-07-16DirectorCommon Stock Purchase WarrantPurchase687,285—
  • 2026-07-16Chief Executive OfficerCommon Stock Purchase WarrantPurchase34,364—
  • 2026-07-16DirectorPurchase687,285$1000.0K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Cardiff Oncology, Inc. do?

Oncolytics is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor, to treat various cancers by combining it with standard-of-care therapies.

When did CRDF last file with the SEC?

Cardiff Oncology, Inc.'s most recent SEC filing on record is a DEF 14A filed 2026-08-26. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:13 UTC. This page is also available as JSON at /api/data?ticker=CRDF and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CRDF and 5,000+ tickers.

Create a free account — keep CRDF
For your agent
GET /api/data?ticker=CRDF

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt